Evidence map›Paper›PMID 31319816›Full record

ArticleBMC cancer2019

Overweight and obesity as predictors of early mortality in Mexican children with acute lymphoblastic leukemia: a multicenter cohort study.

Juan Carlos Núñez-Enríquez, Ana Elena Gil-Hernández, Elva Jiménez-Hernández, Arturo Fajardo-Gutiérrez, Aurora Medina-Sansón, Janet Flores-Lujano, Laura Eugenia Espinoza-Hernández, David Aldebarán Duarte-Rodríguez, Raquel Amador-Sánchez, José Gabriel Peñaloza-González and 21 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04271215 (Overweight and Obesity as Prognostic Factors for Survival in Children With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04271215 unknown statusnot on this map

Overweight and Obesity as Prognostic Factors for Survival in Children With Acute Lymphoblastic Leukemia

TypeobservationalSponsorCoordinación de Investigación en Salud, MexicoRan2010 to 2022Enrolled1,200ConditionsLeukemia, LymphoblasticArmsChemotherapy protocol used
3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Implications of adipocyte dysfunction in pediatric obesity: a narrative review.Pediatric endocrinology, diabetes, and metabolism · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Pre- and Postnatal Exposures to Tobacco Smoking and Survival of Childhood Acute Lymphoblastic and Myeloid Leukemias in California, United States.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  10. Article
  11. Article
  12. The 'omics of obesity in B-cell acute lymphoblastic leukemia.Journal of the National Cancer Institute. Monographs · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Juan Carlos Núñez-EnríquezUnidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Ana Elena Gil-HernándezUnidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Elva Jiménez-HernándezServicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico.
Arturo Fajardo-GutiérrezUnidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Aurora Medina-SansónServicio de Hemato-Oncologia, Hospital Infantil de México Federico Gómez, Secretaria de Salud (SS), Mexico City, Mexico.
Janet Flores-LujanoUnidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Laura Eugenia Espinoza-HernándezServicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico.
David Aldebarán Duarte-RodríguezUnidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Raquel Amador-SánchezServicio de Hematología Pediátrica, Hospital General Regional "Carlos McGregor Sánchez Navarro", IMSS, Mexico City, Mexico.
José Gabriel Peñaloza-GonzálezServicio de Onco-Pediatria, Hospital Juárez de México, SS, Mexico City, Mexico.
José Refugio Torres-NavaServicio de Oncología, Hospital Pediátrico de Moctezuma, Secretaria de Salud de la Ciudad de México (SSCDMX), Mexico City, Mexico.
Rosa Martha Espinosa-ElizondoServicio de Hematología Pediátrica, Hospital General de México, SS, Mexico City, Mexico.
Luz Victoria Flores-VillegasServicio de Hematología Pediátrica, Centro Médico Nacional "20 de Noviembre", Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico.
Laura Elizabeth Merino-PasayeServicio de Hematología Pediátrica, Centro Médico Nacional "20 de Noviembre", Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico.
María Luisa Pérez-SaldivarUnidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Elisa María Dorantes-AcostaServicio de Hemato-Oncologia, Hospital Infantil de México Federico Gómez, Secretaria de Salud (SS), Mexico City, Mexico.
Beatriz Cortés-HerreraServicio de Hematología Pediátrica, Hospital General de México, SS, Mexico City, Mexico.
Karina Anastacia Solis-LabastidaServicio de Hematología Pediátrica UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico.
Nora Nancy Núñez-VillegasServicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico.
Martha Margarita Velázquez-AviñaServicio de Onco-Pediatria, Hospital Juárez de México, SS, Mexico City, Mexico.
Angélica Rangel-LópezCoordinación de Investigación en Salud, IMSS, Mexico City, Mexico.
Ana Itamar González-ÁvilaServicio de Hematología Pediátrica, Hospital General Regional "Carlos McGregor Sánchez Navarro", IMSS, Mexico City, Mexico.
Jessica Denisse Santillán-JuárezServicio de Hemato-oncología Pediátrica, Hospital Regional No. 1° de Octubre, ISSSTE, Mexico City, Mexico.
Alejandra Jimena García-VelázquezServicio de Hemato-oncología Pediátrica, Hospital Regional No. 1° de Octubre, ISSSTE, Mexico City, Mexico.
Silvia Jiménez-MoralesLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Vilma Carolina Bekker-MéndezUnidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología "Dr. Daniel Méndez Hernández", "La Raza", IMSS, Mexico City, Mexico.
Haydee Rosas-VargasUnidad de Investigación en Genética Humana, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico.
Minerva Mata-RochaUnidad de Investigación en Genética Humana, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico.
Omar Alejandro Sepúlveda-RoblesUnidad de Investigación en Genética Humana, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico.
Jorge Alfonso Martín-TrejoServicio de Hematología Pediátrica UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico. jorge.martintr@imss.gob.mx.
Juan Manuel Mejía-AranguréUnidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. juan.mejiaa@imss.gob.mx.

Funding

Consejo Nacional de Ciencia y Tecnología (CONACYT) SALUD-2010-1-141026, FIS/IMSS/PROT/895; PDCPN2013-01-215726, FIS/IMSS/PROT/1364; SALUD 2015-1-262190, FIS/IMSS/PROT/1533; CB-2015-1-258042, FIS/IMSS/PROT/1548] and FONCICYT/37/2018, FIS/IMSS/PROT/1782]Instituto Mexicano del Seguro Social FIS/IMSS/PROT/PRIO/11/017, FIS/IMSS/PROT/G12/1134, FIS/IMSS/PROT/PRIO/14/031, FIS/IMSS/PROT/MD13/1254, FIS/IMSS/PROT/PRIO/15/048, FIS/IMSS/PROT/MD15/1504, FIS/IMSS/PROT/G15/1477
6 · The paper itself

Abstract

backgroundMexico City has one of the highest incidences and mortality rates of acute lymphoblastic leukemia (ALL) in the world and a high frequency of early relapses (17%) and early mortality (15%). Otherwise, childhood overweight and obesity are reaching epidemic proportions. They have been associated with poor outcomes in children with ALL. The aim of present study was to identify if overweight and obesity are predictors of early mortality and relapse in Mexican children with ALL.

methodsA multicenter cohort study was conducted. ALL children younger than 15 years old were included and followed-up during the first 24 months after diagnosis. Overweight and obesity were classified according World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria. Early mortality and early relapses were the main outcomes.

resultsA total of 1070 children were analyzed. Overweight/obesity at diagnosis were predictors of early mortality (WHO: HR = 1.4, 95%CI:1.0-2.0; CDC: HR = 1.6, 95%CI:1.1-2.3). However, no associations between overweight (WHO: HR = 1.5, 95%CI:0.9-2.5; CDC: HR = 1.0; 95% CI:0.6-1.6) and obesity (WHO: HR = 1.5, 95%CI:0.7-3.2; CDC: HR = 1.4; 95%CI:0.9-2.3) with early relapse were observed.

conclusionsOverweight and obese patients embody a subgroup with high risk of dying during leukemia treatment.

Indexed as

AdolescentBody Mass IndexChildChild, PreschoolDisease-Free SurvivalFemaleFollow-Up StudiesHumansIncidenceInfantMaleMexicoPediatric ObesityPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRecurrenceChildrenEarly mortalityLeukemiaMexicoObesityOverweight

Identifiers

PMID31319816
PMCPMC6639907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.